-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

652.O2.6 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Reoptimizing Standards and Redefining Approaches

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Real World Evidence, Lymphoid Malignancies
Sunday, December 12, 2021: 4:30 PM-6:00 PM
Hall A1 (Georgia World Congress Center)
Moderators:
Juan Du, MD, PhD, Shanghai Changzheng hospital, Naval Medical University and Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami
Disclosures:
Landgren: Amgen: Honoraria, Research Funding; Janssen: Honoraria, Other, Research Funding; Celgene: Research Funding; BMS: Research Funding; Adaptive Biotech: Honoraria; Theradex: Other: IDMC.
The current state of the definitions for multiple myeloma and related precursor conditions include a range of unresolved clinical and scientific questions. Many of these questions can be studied in larger retrospective databases, clinical epidemiology cohort studies, or smaller molecular studies with clinically well-annotated samples. Dr. Burgos will present results from over 5000 cases with monoclonal gammopathies investigated by flowcytometry. Their study shows how an algorithm which can be installed in clinical flow cytometry software can be used to generate automated classifications across the spectrum of monoclonal gammopathies. Dr. Long will discuss how current reference intervals for serum free light-chain (FLC) and FLC-ratio are inaccurate for patients with decreased kidney function. Based on the large prospective iStopMM study, new reference intervals will be proposed for serum FLC and FLC-ratio, for use in patients with chronic kidney disease which also seem to be accurate in patients on dialysis. Dr. Visram will address that current smoldering multiple myeloma (SMM) prognostication models - routinely used in clinical practice - indeed were developed for use at diagnosis. This talk will focus on how one dynamically can risk stratify patients post-diagnosis, and how to better identify patients with evolving disease. Dr. Puig will discuss comparisons of blood based immunofixation electrophoresis (IFE), quantitative immunoprecipitation mass spectrometry, liquid chromatography mass spectrometry (LC-MS), and bone marrow-based MRD assays. Focus of the investigations include capacity to identify the presence of disease and ability to determine prognosis. Dr. Samur will present results from their studies designed to distinguish genomic hallmarks of low-risk (vs high-risk) smoldering multiple myeloma. Using transcriptome, epigenome and whole genome profiling they have interrogated samples from patients with clinical follow-up data. Dr. Jelinek will discuss findings from their study investigating circulating plasma cells (sPCs) measured by 8 color flow cytometry in 402 multiple myeloma patients. Scope of these investigations is to evaluate the prognostic significance of cPCs, and also to define cut-offs for risk stratification.
4:30 PM

Leire Burgos1*, Luis Esteban Tamariz-Amador, MD2*, Noemí Puig, MD, PhD3*, María Teresa Cedena, MD, PhD4*, Tomas Jelinek, MD, PhD5, Sarah K Johnson, PhD6, Paolo Milani, MD, PhD7, Lourdes Cordon8*, José J Pérez3*, Marta Lasa1*, Rosalinda Termini9*, Albert Oriol, MD10*, Miguel-Teodoro Hernández, MD, PhD11*, Luis Palomera, MD, PhD12*, Rafael Martinez Martinez13*, Javier de la Rubia, MD, PhD14*, Felipe De Arriba, PhD15*, Rafael Rios, MD, PhD16*, Maria Esther González17*, Mercedes Gironella, MD18*, Valentin Cabañas, MD19*, Maria Casanova, MD20*, Isabel Krsnik21*, Albert Pérez, MD22*, Veronica Gonzalez De La Calle, MD, PhD23*, Paula Rodríguez-Otero, MD, PhD24*, Vladimir Maisnar, MD25*, Roman Hajek, MD, PhD26, Frits van Rhee, MD PhD27, Victor H Jimenez-Zepeda, MD28, Giovanni Palladini29, Paolo Milani30*, Alberto Orfao, MD, PhD3, Laura Rosinol31*, Joan Bladé Creixenti32, Joaquín Martínez-López33*, Juan-José Lahuerta, MD, PhD34*, Maria-Victoria Mateos35, Jesús F. San-Miguel1 and Bruno Paiva, PhD1*

1Centro de Investigación Médica Aplicada, University of Navarra, IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Spain
2Centro de Investigación Médica Aplicada, University of Navarra, IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Navarra, Spain
3Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
4Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain
5Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
6Myeloma Center/Division of Hematology Oncology/Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
7Amyloidosis Research and Treatment Center, Department of Molecular Medicine, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
8Hospital Universitario La Fe, Valencia, Spain
9Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain
10Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
11Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
12Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
13Hospital Clínico San Carlos, Madrid, Spain
14Hematology Department, University Hospital La Fe, Valencia, Spain
15Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
16Hospital Universitario Virgen de las Nieves de Granada, Instituto de Investigación Biosanitaria IBS GRANADA, Granada, Spain
17Hospital de Cabueñes, Gijón, Spain
18Department of Hematology, University Hospital Vall d’Hebron, Barcelona, Spain
19Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Arrixaca. University of Murcia, Murcia, Spain
20Hematology Department, Hospital Costa del Sol Marbella, Marbella, Spain
21Hospital Universitario Puerta de Hierro, Hospital, Madrid, Spain
22Hospital Universitario Son Espases, Palma, Spain
23Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
24Clinica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Navarra, Spain
254th Department of Medicine - Haematology, Charles University Hospital, Hradec Králové, Czech Republic
26Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
27Myeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
28Tom Baker Cancer Center, Department of Hematology, University of Calgary, Calgary, AB, Canada
29Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, PV, Italy
30Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matt, Pavia, ITA
31Amyloidosis and Myeloma Unit. Department of Hematology. Hospital Clínic de Barcelona. IDIBAPS., Barcelona, Spain
32Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clínic, Barcelona, Spain, Barcelona, Spain
33Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, CNIO, CIBERONC, Madrid, Spain
34Hospital 12 de Octubre, CIBERONC, Madrid, Spain
35Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain

4:45 PM

Thorir Einarsson Long, MD, PhD1,2*, Olafur Skuli Indridason, MD, MHS3*, Runolfur Palsson, MD4,5*, Sæmundur Rögnvaldsson, MD5*, Thorvardur Jon Love, MD, PhD6*, Sigrun Thorsteinsdottir, MD, PhD6,7, Ingigerdur Solveig Sverrisdottir, MD, BSc5*, Brynjar Vidarsson, MD4, Pall Torfi Onundarson, MD4, Bjarni Agnar Agnarsson, MD4*, Margret Sigurdardottir, MD4*, Ingunn Thorsteinsdottir, MD, PhD4*, Isleifur Olafsson, MD, PhD4*, Asdis Rosa Thordardottir6*, Elias Eythorsson, MD, PhD4*, Asbjorn Jonsson, MD4*, Gauti Gislason8*, Andri Olafsson6*, Hlif Steingrimsdottir, MD9*, Petros Kampanis, PhD10*, Malin Hultcrantz, MD PhD11, Brian G.M. Durie, MD12, Stephen Harding, PhD13, Ola Landgren, MD14 and Sigurdur Yngvi Kristinsson, MD, PhD4,6

1University of Iceland, Reykjavik, AL, Iceland
2Skånes University Hospital, Lund, Sweden
3Landspitali–The National University Hospital of Iceland, Reykjavik, Iceland
4Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
5Faculty of Medicine, University of Iceland, Reykjavík, Iceland
6Faculty of Medicine, University of Iceland, Reykjavik, Iceland
7Department of Hematology, Rigshospitalet, Copenhagen, Denmark
8University of Iceland, Reykjavik, ISL
9Landspitali - National University Hospital of Iceland, Reykjavík, Iceland
10Binding Site Group Ltd., Birmingham, ENG, United Kingdom
11Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
12Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
13The Binding Site Inc., Birmingham, United Kingdom
14Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami

5:00 PM

Alissa Visram, alisvisram@toh.ca1*, S. Vincent Rajkumar, MD2*, Prashant Kapoor, MD2, Angela Dispenzieri, MD2, Martha Q. Lacy, MD3, Morie A. Gertz, M.D.2, Francis K. Buadi, MB, CHB4*, Suzanne R. Hayman, M.D.2, David Dingli, M.D., Ph.D.2, Taxiarchis Kourelis, M.D.2, Wilson I Gonsalves, MD2, Rahma M Warsame, MD2, Eli Muchtar, MD2, Nelson Leung, MD3, Linda B Baughn, PhD5, Robert A. Kyle, MD2 and Shaji K Kumar, MD6

1Division of Hematology, Mayo Clinic, Rochester
2Division of Hematology, Mayo Clinic, Rochester, MN
3Division of Hematology, Mayo Clinic Rochester, Rochester, MN
4Mayo Clinic Rochester, Division of Hematology, Rochester, MN
5Division of Laboratory Genetics, Mayo Clinic, Rochester, MN
6Mayo Clinic, Rochester, MN

5:15 PM

Noemi Puig, MD, PhD1,2, Teresa Contreras Sanfeliciano3*, Bruno Paiva, PhD4*, María Teresa Cedena, MD, PhD5*, Laura Rosinol6*, Ramón Garcia-Sanz, MD, PhD2, Joaquín Martínez-López7,8,9,10*, Albert Oriol11*, María Jesús Blanchard, MD12*, Rafael Rios, MD, PhD13*, Jesus Martin, MD14*, Anna Sureda15, Miguel Hernández16*, Javier De La Rubia, MD17*, Isabel Krsnik, MD, PhD18*, Jose Maria Moraleda, MD, PhD19*, Belén Iñigo, MD20*, Luis Palomera, MD, PhD21*, Cristina Agulló1*, Joan Bargay22*, Joan Bladé Creixenti23,24, Jesús San-Miguel, MD, PhD4,25, Juan-José Lahuerta, MD, PhD26* and Maria-Victoria Mateos27,28,29

1University Hospital of Salamanca, Salamanca, Spain
2Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
3Servicio Análisis Clínicos y Bioquímica Clínica del Complejo Asistencial Salamanca, Complejo Asistencial Salamanca, Salamanca, Spain
4Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
5Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain
6Hematology, Hematology Department, Hospital Clinic i Provincial, IDIBAPS, Barcelona, Spain
7Hospital 12 De Octubre, Madrid, Spain
8H12O-CNIO Clinical research unit, CIBERONC, Complutense University, Madrid, Spain
9Department of Hematology, Hospital Universitario 12 de Octubre; H12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain
10Hematology Department, Hospital Universitario 12 de Octubre, CNIO, Complutense University, Madrid, Spain
11Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
12Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain
13Hospital Universitario Virgen de las Nieves de Granada, Instituto de Investigación Biosanitaria IBS GRANADA, Granada, Spain
14Hospital Universitario V. Rocio, Sevilla, ESP
15Clinical Hematology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
16Hospital Universitario de Canarias, Santa Cruz de Tenerife, La Laguna, ESP
17Hospital Universitari i Politècnic La Fe, Catholic University of Valencia, Valencia, Spain
18Hospital Universitario Puerta de Hierro, Madrid, Spain
19Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Arrixaca. University of Murcia, Murcia, ESP
20Hospital Universitario Clínico San Carlos, Madrid, Spain
21Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
22Hospital Universitario Son Llatzer, Institut d’ investigacio Illes Balears (IdISBa), Palma de Mallorca, Spain
23Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
24Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain
25Hematology Department, Clínica Universidad De Navarra, Pamplona, Spain
26Instituto de Investigación del Hospital Universitario 12 de Octubre, European Network, Spain
27Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Salamanca, Spain
28CIBERONC, Salamanca, Spain
29Hospital Universitario Salamanca, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain

5:30 PM

Anil Aktas-Samur, PhD1*, Mariateresa Fulciniti, PhD2, Sanika Derebail, MS3*, Raphael Szalat, MD, PhD4, Giovanni Parmigiani, PhD5*, Jill Corre6*, Herve Avet-Loiseau7*, Mehmet K. Samur, PhD8 and Nikhil C. Munshi, MD, PhD9

1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
3Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA
5Dana-Farber Cancer Institute, Boston, MA
6Unité de Génomique du Myélome, IUCT- Oncopole, Toulouse, France
7Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
8Department of Data Science, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA
9Dana-Farber Cancer Institute, Harvard Medical School, Boston

5:45 PM

Tomas Jelinek1, Renata Bezděková2*, David Zihala3*, Tereza Sevcikova3*, Lenka Capkova4*, Petra Polackova2*, Martin Stork5*, Zdenka Knechtova2*, Ondrej Venglar, MSc6*, Artur Jurczyszyn, MD7*, Jorge J. Castillo, MD8, Miroslav Penka2*, Jakub Radocha, MD, PhD9*, Sabina Sevcikova10, Ludek Pour, MD5*, Lucie Rihova2* and Roman Hajek, MD, PhD1

1Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
2Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
3Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
4Institute of biostatistics and analyses, Ltd., Brno, Czech Republic
5Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
6Faculty of Science, University of Ostrava, Ostrava, Czech Republic
7Plasma Cell Dyscrasia Center, Jagiellonian University Department of Hematology, Faculty of Medicine,, Kraków, Poland
8Dept. of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Bing Center for Waldenström Macroglobulinemia, Boston, MA
94th Department of Internal Medicine – Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
10Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, LF Masaryk University, Brno, Czech Republic

*signifies non-member of ASH